Delcath Systems, Inc. issued its full year 2025 financial guidance, projecting total revenue of $94 to $98 million. This guidance represents an increase of more than 150% over the total revenue reported for 2024.
The company anticipates that total HEPZATO treatment volume in 2025 will increase by at least 200% compared to 2024, based on current center activation rates and rising utilization. This outlook underscores the strong commercial momentum for HEPZATO KIT.
Delcath also announced its intention to enter into a National Medicaid Drug Rebate Agreement (NDRA) with the Centers for Medicare and Medicaid Services. This agreement, expected to take effect at the beginning of the third quarter of 2025, will simplify Medicaid access and enable eligible hospitals to access 340B drug pricing, thereby expanding treatment availability and accelerating HEPZATO adoption in the United States.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.